Patents Issued in July 17, 2008
-
Publication number: 20080171689Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: July 24, 2006Publication date: July 17, 2008Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20080171690Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.Type: ApplicationFiled: October 30, 2007Publication date: July 17, 2008Applicant: CORIXA CORPORATIONInventors: Robert A. Henderson, Tongtong Wang, Yoshihiro Watanabe, Michael D. Kalos, Paul R. Sleath, Jeffrey C. Johnson, Marc W. Retter, Margarita Durham, Darrick Carter, Gary R. Fanger, Thomas S. Vedvick, Chaitanya S. Bangur, Andria McNabb
-
Publication number: 20080171691Abstract: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.Type: ApplicationFiled: January 24, 2008Publication date: July 17, 2008Inventors: Leif Roge Lund, Keld Dano, Ross Stephens, Nils Brunner, Helene Solberg, Claus Holst-Hansen, John Romer Nielsen
-
Publication number: 20080171692Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: February 1, 2008Publication date: July 17, 2008Inventors: William K. Hagmann, Linus S. Lin, Shrenik K. Shah, Ravindra N. Guthikonda, Hongbo Qi, Linda L. Chang, Ping Liu, Helen M. Armstrong, James P. Jewell, Thomas J. Lanza
-
Publication number: 20080171693Abstract: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.Type: ApplicationFiled: February 19, 2008Publication date: July 17, 2008Applicant: UNIVERSITY OF MASSACHUSETTS MEDICAL CENTERInventors: Dario C. Altieri, Janet Plescia, Whitney Salz
-
Publication number: 20080171694Abstract: The invention provides a pharmaceutical formulation and a method for preparing the formulation.Type: ApplicationFiled: October 5, 2005Publication date: July 17, 2008Applicant: NOVO NORDISK A/SInventors: Petter Lybeck (Berghlund), Charlotte Hammelev, Lone Eskildsen, Johanne Madsen, Helle Aalund Olsen, Lone Kimer
-
Publication number: 20080171695Abstract: The present invention is related to insulin derivatives having a side chain attached either to the ?-amino group of the N-terminal amino acid residue of B chain or to an ?-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond which side chain comprises one or more residues of ethyleneglycol, propyleneglycol and/or butyleneglycol containing independently at each termini a group selected from —NH2 and —COOH; a fatty diacid moiety with 4 to 22 carbon atoms, at least one free carboxylic acid group or a group which is negatively charged at neutral pH; and possible linkers which link the individual components in the side chain together via amide or ether bonds, said linkers optionally comprising a free carboxylic acid group.Type: ApplicationFiled: February 1, 2006Publication date: July 17, 2008Applicant: Novo Nordisk A/SInventors: Patrick William Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Svend Havelund, Peter Madsen, Palle Jakobsen
-
Publication number: 20080171696Abstract: Compositions containing an N-linked oligosaccharide having little or no terminal sialic acid residues which is attached to a therapeutic protein that is bonded to a glycol polymer.Type: ApplicationFiled: March 14, 2008Publication date: July 17, 2008Inventor: Kyle D. Yesland
-
Publication number: 20080171697Abstract: The invention relates to cyclised peptides corresponding to sequence SEQ ID No1: X1X2RGDX3FGX4X5LLFIHFX6IGSX7HSX8IX9, wherein: the letters without any numerical index correspond to amino acids defined by the single-letter international code; X1 is G or GG having an amino-terminal end which may or may not be free; X2 is either a C, in which case X2=X4, the two Cs being connected by a disulphide bridge, or X2 is capable of forming a lactam bridge with X4, either X2 or X4 being an amino acid bearing an acid group, such as A or D, and the other bearing an amino function such as Q, N; X3 is either an M pattern or a norleucine pattern; X5 is one or several di-, tri-, or tetra-peptide patterns comprising G or a combination of G and S, or X5 is a C pattern having a side-chain which serves as a covalent linkage point with a 3-nitro-2-pyridinesulphenyl group which is located at the N-terminal end of the next amino acid (L); X6 is either an R pattern or a K pattern; X7 is either an R pattern or a K pattern; X8 is eitherType: ApplicationFiled: September 24, 2004Publication date: July 17, 2008Inventors: Etienne Jacotot, Annie Borgne-Sanchez, Sylvie Dupont, Dominique Rebouillat
-
Publication number: 20080171698Abstract: The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention particularly relates to the preparation of novel Angiotensin Converting Enzyme Inhibitors (ACEI) with prolonged activity. ACE inhibitors play an important role in Re -Angiotensin-Aldosteron system (RAAS) by inhibiting the activity of Angiotensin Converting Enzyme (ACE) and therefore are used to regulate blood pressure. ACE inhibitors synthesized by the process of present invention have a peptide moiety and nonpeptide moiety. ACE inhibitors, synthesized by this present invention, show enhanced bioavailability and fewer side effects.Type: ApplicationFiled: August 28, 2007Publication date: July 17, 2008Inventors: Santosh Pasha, Qadar Pasha, Kashif Hanif, Mahesh Chand Pavar
-
Publication number: 20080171699Abstract: The invention relates to novel cyclic peptide derivatives of general formula (I): wherein A, B, R1 and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus.Type: ApplicationFiled: November 19, 2007Publication date: July 17, 2008Inventors: Andrew William Scribner, David Renwick Houck
-
Publication number: 20080171700Abstract: The present invention relates to the use of a growth hormone (GH) secretagogue, such as a ghrelin-like compound, for the preparation of a medicament for the prophylaxis or treatment of ghrelin deficiency, and/or undesirable symptoms associated therewith, in an individual at risk of acquiring partial or complete ghrelin deficiency resulting from a medical treatment and/or from a pathological condition. The present invention also relates to use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of one or more of: loss of fat mass, loss of lean body mass, weight loss, cachexia, loss of appetite, immunological dysfunction, malnutrition, disrupted sleep pattern, sleepiness, reduction in intestinal absorption and/or intestinal mobility problems in an individual suffering from, or at risk of suffering from, ghrelin deficiency.Type: ApplicationFiled: April 7, 2005Publication date: July 17, 2008Applicant: Gastrotech Pharma A/SInventors: Henrik Nilsson, Birgitte Holst Lange, Claes Post, Tina Geritz Nielsen
-
Publication number: 20080171701Abstract: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels.Type: ApplicationFiled: August 20, 2007Publication date: July 17, 2008Inventors: David M. Stern, Ann Marie Schmidt, Steven Marso, Eric Topol, A. Michael Lincoff
-
Publication number: 20080171702Abstract: The present invention relates generally to a nucleic acid molecule which encodes a protein associated with the modulation of obesity, diabetes and metabolic energy levels. More particularly, the present invention is directed to a nucleic and a recombinant and purified naturally occurring protein encoded thereby and their uses in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid molecule and protein and their derivatives, homologues, analogues and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance.Type: ApplicationFiled: December 5, 2007Publication date: July 17, 2008Applicants: International Diabetes Institute, Deakin UniversityInventors: Paul Zev ZIMMET, Gregory Collier
-
Publication number: 20080171703Abstract: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).Type: ApplicationFiled: February 29, 2008Publication date: July 17, 2008Inventor: Jesse M. Cedarbaum
-
Publication number: 20080171704Abstract: The present invention comprises dosing regimens and formulations of islet cell neogenesis associated protein (INGAP) and INGAP Peptide. The formulation disclosed herein is shown have acceptable stability as a pharmaceutical composition. Further, the formulation is able to regenerate functional islets.Type: ApplicationFiled: December 4, 2007Publication date: July 17, 2008Inventors: Aaron I. Vinik, Lawrence Rosenberg, Gary Pittenger, David Taylor-Fishwick, Michael Salem, Scott Mohrland
-
Publication number: 20080171705Abstract: Animal testing, wherein the animals have disease state characteristics substantially equivalent to those found in humans, may be utilized to evaluate the efficacy of medical devices and/or therapeutic agents.Type: ApplicationFiled: December 12, 2007Publication date: July 17, 2008Inventors: Robert Falotico, Jonathon Z. Zhao, Lei Zhao
-
Publication number: 20080171706Abstract: The present invention provides compounds and compositions capable of inhibiting the attachment of Gram-negative bacteria on a host epithelium.Type: ApplicationFiled: March 23, 2005Publication date: July 17, 2008Applicant: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Jenny Berglund, Julie Bouckaert, Henri De Greve, Stefan Knight
-
Publication number: 20080171707Abstract: The invention concerns the use of an onion extract comprising 20 wt. % to 40 wt. % of polyphenols of the flavonol family, said onion extract having the following composition characteristics, expressed in weight relative to the total extract dry weight: 60 wt. % to 90 wt. % of the total flavonols of said extract consist of glycosylated polyphenols; 85 wt. % to 98 wt. % of total flavonols of said extract consist of free-form (aglycon) or glycosylated quercetin; 5 wt. % to 20 wt. % of the total flavonols of said extract consist of quercetin-3,4?-diglucoside; 30 wt. % to 70 wt. % of the total flavonols of said extract consist of quercetin-3-monoglucoside and quercetin-4?-monoglucoside; and 20 wt. % to 30 wt. % of the total flavonols of said extract consist of quercetin, for making a composition to control weight gain.Type: ApplicationFiled: March 14, 2006Publication date: July 17, 2008Applicant: Scalime NutritionInventors: Marie-Josephe Amiot-Carlin, Christine Juhel, Frederic Tosini, Louis Cara, Veronique Berger
-
Publication number: 20080171708Abstract: The present invention relates to pharmaceutical compositions containing certain flavonoid glycoside-type compounds that have been shown in the present invention to be therapeutically useful, including useful as analgesics and anti-inflammatories for the treatment and management of pain and inflammatory conditions. Methods for the therapeutic uses of such compounds and pharmaceutical compositions is also provided.Type: ApplicationFiled: December 28, 2007Publication date: July 17, 2008Applicant: BMB Patent Holding CorporationInventor: Barry Miles Begorod
-
Publication number: 20080171709Abstract: The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone and beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is antitumoral. The invention is for use in the field of pharmaceutics.Type: ApplicationFiled: May 15, 2006Publication date: July 17, 2008Applicant: ADVANCED SCIENTIFIC DEVELOPMENTSInventor: Adnane Remmal
-
Publication number: 20080171710Abstract: Methods and compositions related to a novel cellular pathway, the redox/Fyn/c-Cbl pathway, include a variety of aspects. Provided herein are agents that selectively interrupt the pathway and methods of using the same. Also provided are screening methods used to identify a pro-oxidation toxicant or other agents and stimuli that affect the redox/Fyn/c-Cbl pathway. Methods of testing oxidation levels by evaluating aspects of the pathway are also provided.Type: ApplicationFiled: January 17, 2007Publication date: July 17, 2008Applicant: UNIVERSITY OF ROCHESTERInventors: Mark Noble, Chris Proschel, Zaibo Li, Brett Stevens, Yin Miranda Yang, Tiefei Dong
-
Publication number: 20080171711Abstract: The present invention relates to a mixture which contains mRNA for vaccination, wherein at least one mRNA contains a domain which codes for at least one antigen from a tumor and at least one further mRNA contains a domain which codes for at least one immunogenic protein (polypeptide). The invention furthermore relates to a pharmaceutical composition which contains an mRNA mixture according to the invention, and to the use for the treatment of tumor diseases.Type: ApplicationFiled: July 20, 2005Publication date: July 17, 2008Inventors: Ingmar Hoerr, Steve Pascolo
-
Publication number: 20080171712Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.Type: ApplicationFiled: April 6, 2007Publication date: July 17, 2008Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Reddy Putta, Sudhir Agrawal
-
Publication number: 20080171713Abstract: A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease and administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease, or comprising a polynucleotide sequence encoding the adenoviral protein E3-GP19k, or comprising a polynucleotide sequence encoding ?BCL-2.Type: ApplicationFiled: August 9, 2007Publication date: July 17, 2008Applicant: LOMA LINDA UNIVERSITYInventors: Alan P. Escher, Fengchun Li
-
Publication number: 20080171714Abstract: A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease and administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease, or comprising a polynucleotide sequence encoding the adenoviral protein E3-GP19k, or comprising a polynucleotide sequence encoding ?BCL-2.Type: ApplicationFiled: August 9, 2007Publication date: July 17, 2008Applicant: LOMA LINDA UNIVERSITYInventors: Alan P. Escher, Fengchun Li
-
Publication number: 20080171715Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: ApplicationFiled: August 10, 2007Publication date: July 17, 2008Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Publication number: 20080171716Abstract: The present invention provides methods of modulating the activation of certain Toll-like receptors (TLRs) such as TLR7/8 using chemically modified nucleic acid molecules. The present invention also provides methods of using such modified nucleic acid molecules to treat diseases or disorders associated with TLR7/8 activation such as systemic lupus erythematosus. The present invention further provides compositions comprising a combination of modified nucleic acid molecules and nucleic acid molecules that silence expression of one or more target sequences. Methods of using such compositions to reduce or abolish target gene expression without inducing cytokine production are also provided.Type: ApplicationFiled: August 15, 2007Publication date: July 17, 2008Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Marjorie Robbins, Adam Judge
-
Publication number: 20080171717Abstract: The invention relates to a synthetic double-stranded oligonucleotide capable of modifying the molecular phenotype of osteoclasts and increasing the expression of the oestrogen alpha receptor gene. Pharmaceutical compositions comprising the oligonucleotide according to the invention are also described, as well as therapeutic applications of that oligonucleotide, in particular for the treatment of osteopenic diseases such as for example osteoporosis. The oligonucleotide according to the invention is characterised in that it comprises the sequence 5?-ATTTATTTTCAATACTGACT-3? or a fragment or a mutant thereof.Type: ApplicationFiled: March 30, 2006Publication date: July 17, 2008Applicants: UNIVERSITA' DEGLI STUDI DI FERRARA, ASSOCIAZIONE VENETA PER LA LOTTA ALLA TALASSEMIAInventors: Roberto Gambari, Letizia Penolazzi, Roberta Piva
-
Publication number: 20080171718Abstract: Methods and compositions are provided for treating cell-proliferative related disorders such as cancer. Methods of inhibiting the growth of cancer cells comprise contacting the cancer cells with a Bcl-2 antisense oligomer; contacting the cancer cells with a tyrosine kinase inhibitor; and contacting the cancer cells with a cytotoxic chemotherapeutic agent. Methods of treating cancer in a human comprise administering to the human a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. Kits containing compositions in amounts sufficient for at least one cycle of treatment comprise a triplet combination therapy of a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. In selected embodiments, the tyrosine kinase inhibitor is one that targets cell surface kinase receptors, such as VEGFR (e.g., VEGFR1, VEGFR2, VEGFR3), PDGFR, KIT, and FLT-3.Type: ApplicationFiled: November 6, 2007Publication date: July 17, 2008Inventor: Bob D. Brown
-
Publication number: 20080171719Abstract: RNA interference is provided for inhibition of aquaporin 1 (AQP1) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.Type: ApplicationFiled: November 28, 2007Publication date: July 17, 2008Applicant: Alcon Manufacturing, Ltd.Inventors: Jon E. Chatterton, Rajkumar V. Patil, Najam A. Sharif, Abbot F. Clark, Martin B. Wax
-
Publication number: 20080171720Abstract: The present invention relates to a nutritional product for HIV patients. More specifically the invention relates to a nutritional composition that provides carefully selected nutritional ingredients including oligosaccharides and cysteine and/or a source of cysteine specifically supporting HIV patients with nutritionally related symptoms. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.Type: ApplicationFiled: April 19, 2006Publication date: July 17, 2008Inventors: Johan Garssen, Eric Alexander Franciscus Van Tol, Johannes Wilhelmus Christina Sijben, George Verlaan
-
Publication number: 20080171721Abstract: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.Type: ApplicationFiled: September 14, 2007Publication date: July 17, 2008Inventor: Bahram Memarzadeh
-
Publication number: 20080171722Abstract: The present invention provides composition and methods for the synthesis of low molecular weight heparins and heparinoids. The present invention also provides compositions having substantially homogenous populations of desired heparin molecules, or molecules useful in the synthesis of heparin oligosaccharides.Type: ApplicationFiled: January 7, 2008Publication date: July 17, 2008Applicant: Academia Sinica, Office of Public Affairs (Technology Transfer)Inventors: Shang-Cheng Hung, Jing-Chyi Lee, Xin-An Lu
-
Publication number: 20080171723Abstract: The present invention relates to novel boronic acid aryl derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good inhibitors of the growth of human breast cancer cells. The present invention also relates to the use of the novel boronic acid aryl derivatives to treat cancer. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of cancer.Type: ApplicationFiled: December 21, 2004Publication date: July 17, 2008Applicant: John Hopkins University, Johns Hopkins Technology TransferInventor: Saeed R. Khan
-
Publication number: 20080171724Abstract: Phosphorus substituted mycophenolate oxime derivatives with anti-cancer, anti-viral, anti-inflammatory anti-tissue/organ transplant rejection properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit tumor growth, viral growth, inflammation, and tissue/organ transplant rejection and/or are useful therapeutically for the treatment or prevention of cancer, viral infection, inflammation and tissue/organ transplant rejection, as well as in assays for the detection of cancer, viral infection, inflammation and tissue/organ transplant rejection.Type: ApplicationFiled: October 26, 2005Publication date: July 17, 2008Applicant: GILEAD SCIENCES, INC.Inventors: William J. Watkins, Aesop Cho
-
Publication number: 20080171725Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.Type: ApplicationFiled: August 10, 2007Publication date: July 17, 2008Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
-
Publication number: 20080171726Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.Type: ApplicationFiled: August 12, 2007Publication date: July 17, 2008Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
-
Publication number: 20080171727Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: ApplicationFiled: October 22, 2007Publication date: July 17, 2008Inventor: Robert A. Ashley
-
Publication number: 20080171728Abstract: Disclosed herein are methods for preparing steroids and Vitamin D derivatives having the unnatural beta (usually S) configuration at C20, the methods comprising the use of compounds of the formula: wherein R is as defined herein. Also disclosed are steroids and Vitamin D derivatives made using the methods disclosed herein and pharmaceutical compositions comprising said steroids and Vitamin D derivatives.Type: ApplicationFiled: January 11, 2008Publication date: July 17, 2008Inventor: Alexander James Bridges
-
Publication number: 20080171729Abstract: A method for enhancing skin permeability by administration of a tetracyclic compound and improved methods for treatment of disorders by administration of a tetracyclic compound and a pharmaceutically active compound.Type: ApplicationFiled: July 15, 2005Publication date: July 17, 2008Inventor: Josef Gottfried Meingassner
-
Publication number: 20080171730Abstract: Methods are provided for preventing or treating risk factors for cardiovascular disease in an individual, comprising administering a therapeutically effective amount of a composition comprising an estradiol metabolite to said individual. Such risk factors include obesity, the metabolic syndrome, diabetes mellitus, vascular disorders, and renal disorders. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol or prodrugs thereof. The compositions may also be in the form of a controlled release formulation. Methods are also provided for use of estradiol metabolites to treat or prevent insulin resistance, vascular endothelial dysfunction, hyperlipidemia, hypertension, diabetic nephropathy, proteinuria and reducing leptin levels. In addition, the methods provide a method of stabilizing glucose levels. These treatments may be used in either gender because of their lack of a feminizing estrogenic effect.Type: ApplicationFiled: November 9, 2005Publication date: July 17, 2008Applicant: University of PittsburghInventors: Edwin K. Jackson, Stevan P. Tofovic, Raghvendra K. Dubey
-
Publication number: 20080171731Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.Type: ApplicationFiled: October 31, 2007Publication date: July 17, 2008Inventor: Gustavo C. Rodriguez
-
Publication number: 20080171732Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.Type: ApplicationFiled: January 11, 2008Publication date: July 17, 2008Applicant: AstraZeneca ABInventors: Thomas Antonsson, Ruth Bylund, Johan Johansson, Peter Bach, David Brown, Fabrizio Giordanetto
-
Publication number: 20080171733Abstract: A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.Type: ApplicationFiled: March 19, 2008Publication date: July 17, 2008Applicant: ABBOTT LABORATORIESInventors: William A. Carroll, Arturo Perez-Medrano, Alan S. Florjancic, Derek W. Nelson, Sridhar Peddi, Tongmei Li, Eric M. Bunnelle, Gavin Hirst, Biqin C. Li
-
Publication number: 20080171734Abstract: The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).Type: ApplicationFiled: October 22, 2007Publication date: July 17, 2008Applicant: AstraZeneca ABInventors: Leonie Campbell, Kurt Gordon Pike, Abid Suleman, Michael James Waring
-
Publication number: 20080171735Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.Type: ApplicationFiled: March 10, 2008Publication date: July 17, 2008Applicant: Bristol-Myers Squibb Pharma CompanyInventor: Richard E. Olson
-
Publication number: 20080171736Abstract: Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease and Mild Cognitive Impairment (MCI) include administration of gonadotropin-releasing hormone analogs in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists.Type: ApplicationFiled: June 28, 2007Publication date: July 17, 2008Inventors: Christopher W. Gregory, Patrick S. Smith
-
Publication number: 20080171737Abstract: The present invention is directed to cyclic sulfonamide derivatives of formula I: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behaviorial disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.Type: ApplicationFiled: December 12, 2007Publication date: July 17, 2008Applicant: WyethInventors: Andrew Fensome, Joel Adam Goldberg, Casey Cameron McComas, Charles William Mann, Edward George Melenski, Joseph Peter Sabatucci, Richard Page Woodworth
-
Publication number: 20080171738Abstract: A method of treating a patient with breast cancer includes administering to the patient a breast cancer cell proliferation-inhibiting amount of a methylol-containing compound such as taurolidine, taurultam or a mixture thereof.Type: ApplicationFiled: January 2, 2008Publication date: July 17, 2008Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIEInventors: H. Paul Redmond, Rolf W. Pfirrmann